Literature DB >> 9920090

High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents.

J C Schaer1, J C Reubi.   

Abstract

Gastrin and cholecystokinin (CCK) are two major regulatory peptides synthesized by human gut and brain tissues as well as by selected tumors, in particular gastrin-producing neuroendocrine tumors. In the present study we have evaluated gastrin and CCK gene expression in a group of primary human tumors, including neuronal, renal, and myogenic stem cell tumors, using in situ hybridization techniques. In addition, CCK-A and CCK-B receptors were evaluated in the same group of tumors with receptor autoradiography. Most tumors had gastrin messenger ribonucleic acid (mRNA): 10 of 11 medulloblastomas, 5 of 5 central primitive neuroectodermal tumors, 11 of 11 Ewing sarcomas, 8 of 10 neuroblastomas, 4 of 4 Wilms' tumors, 5 of 5 rhabdomyosarcomas, and 10 of 10 leiomyosarcomas. CCK mRNA was restricted predominantly to Ewing sarcomas (9 of 11) and leiomyosarcomas (5 of 10). CCK-A and CCK-B receptors were not frequently found in these tumors, except for leiomyosarcomas. These data suggest that gastrin and CCK may play a previously unrecognized role in this group of human stem cell tumors. If the increased gastrin mRNA indeed translates into increased gastrin production, measurement of gastrinemia may have a diagnostic significance in the early detection of these tumors. As these two hormones have been reported to act as potent growth factors, they may be of pathophysiological relevance for patients with such stem cell tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920090     DOI: 10.1210/jcem.84.1.5400

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Stimulation of proliferation in the colorectal mucosa by gastrin precursors is blocked by desferrioxamine.

Authors:  Audrey Ferrand; Shamilah Lachal; Gianni Bramante; Suzana Kovac; Arthur Shulkes; Graham S Baldwin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-15       Impact factor: 4.052

Review 2.  Role of gastrointestinal hormones in neuroblastoma.

Authors:  W Clay Gustafson; Brittany B De Berry; B Mark Evers; Dai H Chung
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

3.  Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.

Authors:  Eyup Akgün; Meike Körner; Fan Gao; Kaleeckal G Harikumar; Beatrice Waser; Jean Claude Reubi; Philip S Portoghese; Laurence J Miller
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

4.  Immunohistochemical examination of gastrin, gastrin precursors, and gastrin/CCK-2 receptor in human esophageal squamous cell carcinomas.

Authors:  Aping Yuan; Jinzhong Liu; Yiqing Liu; Tone Bjørnsen; Andrea Varro; Guanglin Cui
Journal:  Pathol Oncol Res       Date:  2008-04-26       Impact factor: 3.201

5.  Altered renal morphology in transgenic mice with cholecystokinin overexpression.

Authors:  Marina Aunapuu; Peeter Roosaar; Tõnu Järveots; Kaido Kurrikoff; Sulev Kõks; Eero Vasar; Andres Arend
Journal:  Transgenic Res       Date:  2008-08-22       Impact factor: 2.788

Review 6.  Potential approaches to the treatment of Ewing's sarcoma.

Authors:  Hongjiu Yu; Yonggui Ge; Lianying Guo; Lin Huang
Journal:  Oncotarget       Date:  2017-01-17

7.  Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract: A case report.

Authors:  Angelo Pirozzi; Ferdinando Riccardi; Grazia Arpino; Carmela Mocerino; Severo Campione; Carlo Molino; Giacomo Cartenì
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

Review 8.  EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma.

Authors:  Florencia Cidre-Aranaz; Javier Alonso
Journal:  Front Oncol       Date:  2015-07-20       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.